- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00896610
Natural History of Autoimmune Diabetes and Its Complications
Background:
- Diabetes is a disease defined by abnormally high blood sugar (glucose) levels. Glucose is an essential source of energy for the body s cells, but insulin is required to move the glucose into the cells. Insulin is a hormone produced by the pancreas that allows glucose to enter cells.
- In diabetes, the body is unable to supply enough insulin to meet its demands. The problem may be a low supply of insulin or a high demand for insulin. Someone who has been diagnosed with diabetes has lost much of their insulin-producing capacity. Clinical studies have shown that good control of blood sugar is essential to prevent diabetes complications like damage to the eyes, kidneys, nerves, and blood vessels.
Objectives:
- To establish a relationship with several individuals with diabetes caused by the immune system attacking the body s insulin-producing cells in order to:
- Explore why the immune system attacks insulin-producing cells.
- Understand why some individuals develop diabetes-related complications and others do not.
- Develop therapies to improve how patients can control their blood sugar levels.
- Continue to follow subjects who have completed or are considering other NIH diabetes-related studies.
- To develop improved tests for determining an individual s risk for developing diabetes and/or to accurately diagnose the exact type of diabetes.
Eligibility:
- Individuals who have been diagnosed with or are at risk for developing diabetes.
Design:
- Standard physical examination and clinical tests to determine if the patient has diabetes or to confirm a particular type of diabetes:
- None of the treatment in this study is experimental.
- Patients will receive a separate consent form for any special tests needed to learn more about their particular type of diabetes.
- Patients may be asked to provide additional urine and blood samples for use in laboratory research about diabetes.
- Researchers may offer medical treatment advice for diabetes, or explain how to improve patients diabetes management skills.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
-INCLUSION CRITERIA:
i. Clinical diagnosis of diabetes, either type 1 (T1D) or insulin-requiring type 2 (T2D),
ii. Healthy individuals who may be at risk for developing diabetes,
iii. Individuals with suspected immune mediated diabetes,
iv. Willingness of the patient or guardian to give informed consent and assent.
EXCLUSION CRITERIA:
i. Concomitant medical problems which would confound the interpretation studies of the autoimmune beta cell destructive process
ii. Concomitant medical, surgical, or other conditions for which adequate facilities or funds are not available to support their care at the NIH.
iii. Any other co-existing condition/circumstances that would make a subject unsuitable to participate in the study, as deemed by the investigators.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Diabetes
Individuals who have been diagnosed with or are at risk for developing diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose level
Time Frame: every 3 months
|
Blood glucose level within a range appropriate for the patient's condition.
|
every 3 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Harlan DM, von Herrath M. Immune intervention with anti-CD3 in diabetes. Nat Med. 2005 Jul;11(7):716-8. doi: 10.1038/nm0705-716. No abstract available.
- Haines L, Wan KC, Lynn R, Barrett TG, Shield JP. Rising incidence of type 2 diabetes in children in the U.K. Diabetes Care. 2007 May;30(5):1097-101. doi: 10.2337/dc06-1813. Epub 2007 Jan 26.
- Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes. 2005 Dec;54 Suppl 2:S62-7. doi: 10.2337/diabetes.54.suppl_2.s62.
- Lo B, Swafford AD, Shafer-Weaver KA, Jerome LF, Rakhlin L, Mathern DR, Callahan CA, Jiang P, Davison LJ, Stevens HE, Lucas CL, White J, von Borstel R, Todd JA, Lenardo MJ. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. J Transl Med. 2011 Nov 28;9:203. doi: 10.1186/1479-5876-9-203.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 090140
- 09-DK-0140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China